Investment Strategy


  • Disaster du Jour: Taomee     Wednesday, 17 Aug 2011 | 2:55 PM ET

    CNBC's Herb Greenberg has the detail on Taomee expecting a decline in Q3 net income.

  • M.I.A. IPOs     Wednesday, 17 Aug 2011 | 2:51 PM ET

    CNBC's Kate Kelly has the story on no deals on the docket this month.

  • Investors should stick to the sidelines on Hewlett-Packard ahead of its Thursday earnings report, said one analyst.

  • Tale of Two Retailers     Wednesday, 17 Aug 2011 | 2:34 PM ET

    Highlighting two standout names in the retail sector, with Jennifer Davis, Lazard, and a look at some bright spots in the industry, with Laura Champine, Cowen and Company.

  • Lights Out On Solar Stocks?     Wednesday, 17 Aug 2011 | 2:19 PM ET

    Are big solar names in trouble? Insight with Gordon Johnson, Axiom Capital.

  • Wells Fargo Changing Loan Limit     Wednesday, 17 Aug 2011 | 2:10 PM ET

    CNBC's Diana Olick has the details on Wells Fargo no longer accepting conforming loans over $625K.

  • What's Dell's Damage?     Wednesday, 17 Aug 2011 | 2:09 PM ET

    CNBC's Herb Greenberg takes a look at what went wrong with Dell.

  • Market Amnesia?     Wednesday, 17 Aug 2011 | 2:02 PM ET

    The market has calmed down from last week. Insight on where they are headed from here, with Joshua Brown, Fusion Analytics and Mark Kiesel, Pimco.

  • It's Time to Buy Banks: Sandler O'Neill's Albertson Wednesday, 17 Aug 2011 | 1:53 PM ET

    During the past month, investors have overreacted to the downside in their trading of the financial sector, and now is the time to buy, says Robert Albertson, chief strategist at Sandler O'Neill.

  • Trader Triple Play     Wednesday, 17 Aug 2011 | 1:50 PM ET

    Weighing in on where the markets are headed, with John Brady, MFGlobal; Matthew Cheslock, Cohen Capital Group, and Jeff Grossman, BRG Brokerage.

  • Back to School Sales Trends     Wednesday, 17 Aug 2011 | 1:37 PM ET

    A look at what's hot at this year's back to school sales, including footwear, with Randy Konik, Jefferies; Jeff Klinefelter, Piper Jaffray, and CNBC's Kayla Tausche.

  • Buyer Exhaustion Coming? Wednesday, 17 Aug 2011 | 1:11 PM ET

    This is clearly a case of seller exhaustion, but we are seeing very little buyer enthusiasm. In other words, after the big dropoff markets have drifted up on oversold conditions, and on some attempting to pick up a few bargains.

  • Midday Market Movers     Wednesday, 17 Aug 2011 | 12:55 PM ET

    A look at the stock pops and drops that might not be on your radar.

  • Gold Bubble & Coinstar to Surge?     Wednesday, 17 Aug 2011 | 12:45 PM ET

    The Fast Money traders take a look at where gold prices are headed, and Michael Olson, Piper Jaffray, weighs in on whether Coinstar will create some friendly competition for Netflix.

  • Stock Mutual Funds See Huge Outflow Wednesday, 17 Aug 2011 | 12:35 PM ET

    So much for blaming the volatility on high frequency traders: stock investors took $30 billion out of stock mutual funds (domestic and foreign) for the week ending August 10, according to the Investment Company Institute.

  • WOTS Now: Fear vs. Fundamentals     Wednesday, 17 Aug 2011 | 12:30 PM ET

    The Fast Money traders weigh in on the midday market movers, and Brian Sozzi, Wall Street Strategies, takes a look at the buzz from the retail sector.

  • Empty IPO Calendar     Wednesday, 17 Aug 2011 | 12:25 PM ET

    CNBC's Kate Kelly takes a look at whether there will be any more IPOs in the near future.

  • Global Recession: Begins & Ends With U.S.?     Wednesday, 17 Aug 2011 | 12:12 PM ET

    Should investors be preparing for a global recession? Insight with Stephen Roach, Morgan Stanley non-executive chairman.

  • 11 Biotech Stocks Hedge Funds Love and Hate Wednesday, 17 Aug 2011 | 12:02 PM ET

    Hedge funds peeled back the curtain this week to reveal a bit about what biotech stocks they were buying and selling during the second quarter.

  • HP Ahead of Earnings     Wednesday, 17 Aug 2011 | 11:50 AM ET

    CNBC's Jon Fortt with a preview of the tech giant's numbers, and discussing whether investors should buy the stock ahead of it's release, with Jim Kelleher, Argus Research.